Literature DB >> 29508750

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.

Jin-An Ma1, Shun Jiang1, Chunhong Hu1, Yangchun Xie1, Tao Hou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29508750     DOI： 10.1016/S1470-2045(18)30074-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.

Authors:  Jianjiao Ni; Tiantian Guo; Yuan Li; Xi Yang; Yida Li; Liqing Zou; Li Chu; Xiao Chu; Shuyan Li; Luxi Ye; Yawei Zhang; Zhengfei Zhu
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 2.  EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Cancer Res       Date:  2019-01       Impact factor: 1.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.